Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
1. NVO raised its guidance for 2025 but reduced sales projections. 2. Compounding competitors are impacting GLP-1 demand significantly. 3. UBS maintains a 'buy' rating, anticipating a relief rally. 4. Q1 showed mixed results, with Ozempic and Wegovy sales fluctuating. 5. U.S. shares rose 5.5% in premarket despite full-year outlook cut.